Bio News
Novartis has discontinued development of the autoimmune disease CAR-T therapy Lapcel and temporarily paused trials across several indications. Novartis identified three cases of immune effector cell-associated hemophagocytic syndrome in trials evaluating lupus, myasthenia gravis and multiple sclerosis, and halted the trials on Aug. 24. Bristol Myers Squibb identified transient and reversible inflammatory reactions in its Zolacel program, voluntarily paused enrollment and is reviewing the clinical data.
BIOBOOK TEAM
biobookmedia@biobook.co.krAspen Neuroscience and Bambusa Plan U.S. IPOs; Developers of Parkinson’s and Bispecific Antibody Therapies
St. Jude Identifies Cell Marker for High-Risk Neuroblastoma
University of Texas at Austin Develops Flexible Electrode for Recording Brain Waves for a Month Without Shaving Hair
Revolution Medicines Shares Fall 6.3% on Concerns About RASONK’s KRAS Subgroup
GSK Adopts Chai Discovery AI Model After Wet-Lab Validation
Teva Wins FDA Approval for Long-Acting Olanzapine Beltruzza for Schizophrenia
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
